A GPC3-targeted siRNA nanovector (NP-siRNA-GPC3 antibody for HCC treatment) showed obvious antitumor efficacy in vitro with minimal toxicity and significantly inhibited orthotopic HCC xenografts (93). This evidence concerns the gene GPC3 and hepatocellular carcinoma.